Last reviewed · How we verify

NCT03549546: POIR

Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.

Completed NA Last updated 26 July 2019
What this trial tests

NA trial testing Blood samples in Lung Cancer in 31 participants. Completed in 12 February 2019.

Timeline
14 June 2018
Primary endpoint
6 February 2019
12 February 2019

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment31
Start date14 June 2018
Primary completion6 February 2019
Estimated completion12 February 2019
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

18 and older, any sex, with Lung Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postoperative pneumonia is one of the most common complications after lung cancer surgery and associated with a morbidity and mortality. Postoperative lymphopenia has been recently identified as one of risk factors for postoperative pneumonia. According to recent studies in polytrauma, cancer or septic shock, T cells dysfunction may be related to high expression of inhibitory receptors on lymphocytes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood samples

Trials testing the same drug.

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03549546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing